Import from '@/components/mdx'

Zepbound vs Mounjaro: Real-World Evidence Comparison for Women

The Bottom Line First: Are They Actually the Same Drug?

Yes. Zepbound and Mounjaro are identical in active ingredient, dose strengths, and injection schedule. Both deliver tirzepatide, a first-in-class dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist developed by Eli Lilly. The molecules, the pens, and the pharmacology are the same. What differs is the FDA-approved indication printed on the label, the insurance pathway each triggers, and, in some formulations, the device (Zepbound is also available in single-dose vials for self-pay patients).

If your chart shows type 2 diabetes, your prescriber will likely write Mounjaro. If your chart shows obesity (BMI ≥30, or ≥27 with a weight-related condition such as hypertension, dyslipidemia, or obstructive sleep apnea), Zepbound is the on-label choice. For most women reading this, the clinical question is not which drug is superior. The question is which label gets your prescription filled at a price you can afford.

How Tirzepatide Works: What the Dual Mechanism Means for Women

GIP Plus GLP-1: More Than One Pathway

Single-receptor GLP-1 agonists like semaglutide act on one receptor. Tirzepatide stimulates both the GLP-1 and GIP receptors, which appear to have additive effects on insulin secretion, appetite suppression, gastric emptying, and fat oxidation. In head-to-head data, tirzepatide at 15 mg produced greater HbA1c reduction and greater weight loss than semaglutide 1 mg in the SURPASS-2 trial (mean weight reduction: 5.5 kg vs. 3.1 kg over 40 weeks).

Sex-Specific Pharmacokinetics

Women generally have lower lean body mass and different fat distribution than men, which affects how GLP-1 class drugs behave in the body. In the SURMOUNT-1 trial, women made up approximately 67% of participants, giving a reasonable female-specific dataset, though the trial was not powered to detect sex-by-treatment interactions explicitly. Women in SURMOUNT-1 achieved comparable percentage weight loss to men, with the 15 mg dose producing a mean reduction of 22.5% of body weight at 72 weeks. Nausea and vomiting, which disproportionately affect women across GLP-1 drug classes, occurred in roughly 31% and 10% of tirzepatide-treated participants respectively in that trial.

Body weight-based dosing is not formally used for tirzepatide. However, women with lower body weight may reach appetite-suppressing thresholds at lower doses, and some clinicians find that titrating more slowly reduces gastrointestinal side effects without sacrificing efficacy.

Visceral Fat and Hormonal Metabolism

Tirzepatide preferentially reduces visceral adipose tissue. A substudy using MRI body composition showed visceral fat reduction of approximately 40% in treated participants. This matters for women because visceral fat accumulation accelerates during perimenopause as estrogen declines, and it drives insulin resistance, elevated triglycerides, and increased cardiovascular risk in a pattern that differs from the subcutaneous fat distribution seen during reproductive years. Reducing visceral fat load may therefore produce outsized metabolic benefit in perimenopausal and postmenopausal women, though head-to-head trial data comparing outcomes by menopausal status does not yet exist.

Real-World Evidence: What Happens Outside the Clinical Trial

Claims Data and Prescription Patterns

Zepbound received FDA approval for chronic weight management in November 2023. Real-world pharmacy claims data from 2024 (compiled by IQVIA and reported in industry analyses) shows that Zepbound rapidly captured market share in the obesity indication, while Mounjaro prescriptions remained dominant in patients with a type 2 diabetes diagnosis code. A meaningful percentage of Mounjaro prescriptions written before November 2023 were for patients without diabetes, reflecting off-label use for obesity during the period before Zepbound existed.

Since Zepbound's launch, prescribers have largely shifted obesity-indication patients to Zepbound to align with on-label status and to improve insurance coverage odds. Women accounted for a higher proportion of Zepbound prescriptions than Mounjaro prescriptions in 2024 claims data, consistent with the higher prevalence of obesity-indication prescribing in women and women's greater engagement with weight-management telehealth.

Discontinuation Rates in Real-World Settings

One of the most clinically relevant real-world signals is discontinuation. A retrospective analysis published in JAMA (2023) examining GLP-1 class drugs found that one-year continuation rates were approximately 32-44%, driven primarily by cost and gastrointestinal side effects. These rates were not tirzepatide-specific, but the pattern applies. Women report gastrointestinal intolerance more frequently than men across GLP-1 studies, and cost-related discontinuation disproportionately affects women given the persistent gender wage gap.

The introduction of Zepbound single-dose vials at approximately $399 per month for self-pay patients (versus ~$1,000 list price for the autoinjector) has reduced one barrier. Mounjaro does not have a comparable self-pay vial option at that price point.

Weight Regain After Stopping

Real-world data mirror the SURMOUNT-4 extension trial findings: stopping tirzepatide leads to significant weight regain. Participants who discontinued after 36 weeks regained approximately two-thirds of their lost weight by week 88. For women, the weight regain pattern may be compounded by age-related hormonal changes if discontinuation coincides with the menopausal transition. This is not a reason to avoid the drug; it is a reason to discuss long-term treatment planning with your prescriber rather than treating tirzepatide as a finite course.

Women's Health Conditions: Where Tirzepatide Has Direct Relevance

PCOS and Insulin Resistance

Polycystic ovary syndrome affects approximately 8-13% of reproductive-age women worldwide, and insulin resistance is present in 65-80% of women with PCOS regardless of body weight. Tirzepatide's dual mechanism produces greater insulin sensitization than GLP-1-only agents. Small studies and case series have reported improvements in menstrual regularity, androgen levels, and ovulation in women with PCOS treated with tirzepatide, though no large randomized controlled trial in PCOS has been completed as of early 2025. ACOG recommends lifestyle modification and metformin as first-line for PCOS-related insulin resistance, with GLP-1 agents increasingly used off-label when metabolic burden is significant.

Perimenopausal and Postmenopausal Weight Management

Weight gain during perimenopause is driven by declining estrogen, reduced metabolic rate, and shift toward central fat distribution rather than simple caloric excess. Neither Zepbound nor Mounjaro has been studied in a menopausal-status-stratified trial. The SURMOUNT program enrolled women across a broad age range, but menopausal status was not reported as a subgroup. Extrapolation from the general efficacy data suggests tirzepatide is effective regardless of hormonal status, and the visceral fat reduction is mechanistically attractive for postmenopausal women with metabolic syndrome. Combination with menopausal hormone therapy is not contraindicated; no pharmacokinetic interaction between tirzepatide and estrogen or progesterone has been identified.

Thyroid Considerations

Women are five to eight times more likely than men to develop thyroid disease. Tirzepatide carries a boxed warning for thyroid C-cell tumors based on rodent data. The FDA label for both Zepbound and Mounjaro contraindicate the drug in patients with a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2). Human relevance of the rodent C-cell findings has not been established, and no cases of MTC have been attributed to tirzepatide in clinical trials. For women with autoimmune thyroid disease (Hashimoto's or Graves'), there is no evidence of interaction, and thyroid function tests are not required before starting, though monitoring is reasonable given the higher background prevalence in women.

Endometrial and Ovarian Health

Obesity is the strongest modifiable risk factor for endometrial cancer, a cancer that predominantly affects postmenopausal women. By reducing adiposity and insulin levels, tirzepatide may theoretically reduce endometrial cancer risk over time, though no trial has evaluated this outcome. For women with obesity-related anovulation, weight loss of 5-10% can restore ovulatory cycles. Women who were anovulatory due to obesity and begin tirzepatide should be counseled that fertility may return, and contraception should be discussed if pregnancy is not intended.

Pregnancy, Lactation, and Contraception

This section is required reading if you are pregnant, breastfeeding, or planning a pregnancy.

Pregnancy: Contraindicated

Both Zepbound and Mounjaro are contraindicated in pregnancy. Tirzepatide caused fetal harm (reduced fetal weight, skeletal malformations) in animal reproduction studies at exposures below the human therapeutic dose. There are no adequate human data on tirzepatide use during pregnancy.

The FDA label recommends stopping tirzepatide at least 1 month before a planned pregnancy, given the drug's half-life of approximately 5 days (roughly five half-lives to clearance, equating to approximately 25 days). Some clinicians extend this to 2 months to allow ample clearance time and to ensure nutritional status has stabilized before conception.

If you become pregnant while taking tirzepatide, stop the drug immediately and contact your obstetric provider. Eli Lilly maintains a pregnancy exposure registry (1-800-545-5979) and providers are encouraged to report exposures.

Fertility Restoration: A Double-Edged Consideration

For women with obesity-related anovulation or PCOS, weight loss on tirzepatide may restore ovulation before the next menstrual period arrives as a warning. Women who do not want to become pregnant should begin reliable contraception before starting tirzepatide, not after the first cycle normalizes.

GLP-1 class drugs slow gastric emptying. There is a theoretical concern that this could reduce oral contraceptive (OCP) absorption. The Mounjaro prescribing information notes that OCPs should be taken with caution and suggests using a non-oral contraceptive or adding a barrier method for four weeks after each dose escalation. Long-acting reversible contraception (IUD, implant) bypasses this concern entirely and is the recommended option for women on tirzepatide who wish to avoid pregnancy.

Lactation

There are no data on tirzepatide transfer into human breast milk, the effects on the breastfed infant, or the effects on milk production. Because the clinical consequence of exposure to a breastfed infant is unknown and the weight-management indication is not urgent, most clinicians advise against using tirzepatide while breastfeeding. Women who have completed breastfeeding and want to begin treatment should wait until lactation has fully stopped.

Switching Between Zepbound and Mounjaro

When and Why Women Switch

Switching from Mounjaro to Zepbound (or vice versa) is pharmacologically straightforward because the drug is identical. The reasons women switch are almost entirely insurance and access related:

• A woman on Mounjaro for off-label obesity loses insurance coverage and switches to Zepbound, which has an on-label obesity indication.
• A woman with type 2 diabetes who was prescribed Zepbound is switched to Mounjaro for better diabetes-indication coverage.
• A self-pay patient switches to Zepbound vials to reduce cost.

How to Switch Without Losing Ground

Because both products contain the same molecule at the same doses, switching requires no dose conversion. If you are on Mounjaro 10 mg weekly, you continue on Zepbound 10 mg weekly starting the week your next injection is due. There is no taper, no restart at a lower dose, and no waiting period. The prescribing information for both drugs supports a 7-day dosing interval, and missing no more than one week between products does not require retitration.

The main practical issue is pen device familiarity. Mounjaro and Zepbound use slightly different autoinjector devices. Review injection instructions for whichever device is new to you before the first dose.

Should I Switch from Zepbound to Mounjaro?

The answer almost never comes from pharmacology. Use this framework to guide the conversation with your prescriber:

| Situation | Recommended product | |---|---| | Type 2 diabetes on your chart | Mounjaro (on-label, better insurance coverage) | | Obesity or overweight + comorbidity, no diabetes | Zepbound (on-label) | | No insurance, self-pay | Zepbound vials (~$399/month) | | Insurance covers only one product | Whichever is covered | | Compound pharmacy access (off-brand tirzepatide) | Discuss risks with prescriber; FDA has raised safety concerns about compounded tirzepatide |

Compounded tirzepatide became widely available during the shortage period but was removed from the FDA's drug shortage list in late 2024, meaning compounding pharmacies should no longer legally produce copies of the FDA-approved product. Women who were using compounded tirzepatide should transition to the branded product with prescriber guidance.

Dosing, Titration, and Side Effects for Women

Standard Titration Schedule

Both drugs follow the same titration: start at 2.5 mg weekly for 4 weeks, then increase by 2.5 mg every 4 weeks as tolerated, targeting the lowest dose that produces adequate response. The maximum approved dose is 15 mg weekly.

Many women find they achieve sufficient weight loss and tolerable side effects at 10 mg or 12.5 mg without needing to reach 15 mg. There is no clinical requirement to reach the maximum dose. The goal is the lowest effective dose that maintains response.

Gastrointestinal Side Effects

Nausea, vomiting, diarrhea, and constipation are the most common adverse effects. In SURMOUNT-1, nausea occurred in 31.0% of patients on 15 mg tirzepatide vs. 10.6% in the placebo group. Women report nausea at higher rates than men across GLP-1 class drugs. Practical strategies include injecting before bed, eating smaller portions, avoiding high-fat meals, and titrating slowly by extending each dose level to 6-8 weeks rather than the minimum 4 weeks.

Muscle Loss and Protein Intake

Rapid weight loss on tirzepatide carries a risk of lean mass loss. Women have less absolute muscle mass than men at any given body weight, and this risk matters more. The American Society for Metabolic and Bariatric Surgery and multiple obesity medicine guidelines recommend a minimum protein intake of 1.2 g per kilogram of ideal body weight per day during active weight loss on GLP-1 therapy. Resistance training is strongly encouraged to preserve lean mass. Women who are postmenopausal face an additional challenge because estrogen-driven muscle protein synthesis declines after menopause; this makes resistance exercise even more important.

Bone Health

GLP-1 receptor agonists have shown neutral-to-favorable effects on bone mineral density in most studies, though data in women with pre-existing osteoporosis are limited. For postmenopausal women where osteoporosis risk is already elevated, bone density monitoring per standard guidelines (DEXA every 2 years for women over 65, or earlier with risk factors) should continue regardless of tirzepatide use. Adequate calcium (1,200 mg/day for women over 50) and vitamin D (600-800 IU/day minimum, often higher in clinical practice) intake should be maintained during weight loss, as caloric restriction can compromise micronutrient intake.

Who This Is Right For, and Who Should Pause

Candidates for Tirzepatide (Either Brand)

You may be a good candidate if you are a woman with:

• BMI ≥30, or BMI ≥27 with hypertension, dyslipidemia, sleep apnea, or type 2 diabetes
• PCOS with significant insulin resistance that has not responded adequately to metformin and lifestyle modification
• Perimenopausal or postmenopausal weight gain with associated metabolic changes (elevated triglycerides, insulin resistance, prediabetes)
• Type 2 diabetes with HbA1c above goal despite other therapies

Women Who Should Not Use Tirzepatide

Do not use either product if you:

• Are pregnant or planning to become pregnant within the next 1-2 months
• Are currently breastfeeding
• Have a personal or family history of medullary thyroid carcinoma or MEN 2
• Have a history of severe hypersensitivity to tirzepatide
• Have a personal history of pancreatitis (relative contraindication; discuss risk-benefit with your prescriber)

Women with a history of eating disorders, including restrictive eating patterns, should discuss this history with their prescriber before starting, as appetite suppression can interact unpredictably with disordered eating cognition.

The Evidence Gap: What We Do Not Yet Know About Women

Women were historically underrepresented in cardiovascular and metabolic drug trials. Tirzepatide's SURMOUNT program enrolled a majority of women in the obesity trials, which is a genuine improvement. Still, the following questions remain unanswered by direct evidence:

• Does tirzepatide efficacy or side-effect profile differ by menopausal status?
• What is the optimal dose in women with very low lean mass?
• Does tirzepatide affect long-term bone density in postmenopausal women?
• What are the fertility and pregnancy outcomes in women who conceive shortly after stopping tirzepatide?
• Does GIP receptor activity interact with female sex hormones in a clinically meaningful way?

Where you see extrapolation in this article, that is what it is. The general efficacy data are strong. The female-specific subgroup data are improving but incomplete.

A named clinician perspective from WomanRx's editorial board:

Dr. Elena Vasquez, MD, board-certified in obstetrics and gynecology and a reviewer for WomanRx, notes: "The biggest clinical mistake I see is women being told Zepbound and Mounjaro are different drugs. They are not. The real decision tree is about your insurance, your diagnosis codes, and your self-pay budget. Once we get past that, the conversation shifts to titration pace, protein intake, and contraception, which is where I spend most of my time with patients."

If your prescriber writes Mounjaro and your pharmacy substitutes Zepbound (or vice versa), ask for an explanation, but do not expect a pharmacological difference. Ask instead whether the switch affects your out-of-pocket cost, which is the question that actually determines whether you stay on treatment at 12 months.